Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
|Slideshows|June 21, 2019
FDA approvals you might have missed
Author(s)Miranda Hester
A look at 5 recent approvals from the US Food and Drug Administration (FDA), including treatment for systemic lupus erythematosus, a new gene therapy, and pain relief for patients with irritable bowel syndrome.
Advertisement
Advertisement
Related to this article
Interim trial findings suggest osteopathic manipulative treatment is feasible and well-tolerated in infants with positional plagiocephaly.
New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
A teddy bear program pairs children with stuffed animals that have matching medical devices to help normalize care and reduce device-related anxiety.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
More than half of firearm-owning parents of children aged 1 to 5 years reported at least 1 firearm stored unlocked, loaded, or both.
The Autus Size-Adjustable Valve can be implanted at about 13 mm and balloon-expanded to 22 mm as children grow, with no deaths or strokes among 62 patients studied.
A 16-month-old with recurrent otitis media developed a spreading unilateral rash on her hip and thigh during antibiotic treatment. PCR testing confirmed herpes zoster, an uncommon diagnosis in young, vaccinated children.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Osteopathic treatment shows safety in infants with plagiocephaly
2
BLA submitted to FDA for Viaskin peanut patch in children aged 4 to 7 years with peanut allergy
3
Ecopipam data at MDS 2026 show early and sustained tic reduction in pediatric Tourette syndrome
4
Teddy Bear Clinic aims to normalize medical devices for pediatric patients
5